Clinical trials: Pembrolizumab
Neoadjuvent, PD-1 Inhibitor
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
The aim of this study was to investigate the efficacy and safety of pembrolizumab combined with albumin paclitaxel and cisplatin versus albumin paclitaxel and cisplatin or 5-fluorouracil and cisplatin in neoadjuvant therapy for…
- Conditions
- Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06006650
- Testing
- Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 114 people
- Sponsor
- Tang-Du Hospital
Head and Neck Squamous Cell Carcinoma
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04193293
- Testing
- Duvelisib, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- SecuraBio
Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
This study will assess the efficacy and safety of pembrolizumab (MK-3475) administered to participants with incurable advanced biomarker-positive solid tumors that have not responded to current therapy or for which current…
- Trial name
- NCT02054806
- Testing
- Pembrolizumab
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
NPC, Locoregionally Advanced Nasopharyngeal Carcinoma
Pembrolizumab + MRGOO3 as Neoadjuvant in NPC
The goal of this clinical trial is to evaluate efficacy and safety of neoadjuvant of the anti PD1 agent Pembrolizumab combined with MRG003 and adjuvant treatment of Pembrolizumab in patients with Epstein-Barr virus (EBV) …
- Trial name
- NCT07267338
- Testing
- Pembrolizumab & MRG003
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Renal Cell Carcinoma
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
- Trial name
- NCT05733715
- Testing
- Pembrolizumab infusion, Lenvatinib tablet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Advanced Ovarian Cancer, Malignant Melanoma
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
This is a phase 1b study for patients with metastatic (cancer has spread to various parts of the body) melanoma and ovarian cancer.
- Trial name
- ACTIVATE (NCT03158935)
- Testing
- Cyclophosphamide, Fludarabine, Pembrolizumab
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma.
- Trial name
- NCT05147558
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in…
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06747585
- Testing
- ALE.P02, Pembrolizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 235 people
- Sponsor
- Alentis Therapeutics AG
Prostatic Neoplasms
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive…
- Trial name
- NCT03007732
- Testing
- Pembrolizumab, SD-101, Leuprolide acetate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- David Oh
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
- Trial name
- NCT03618550
- Testing
- pembrolizumab, gemcitabine, vinorelbine
- Where
- 10 sites in United States
- Volunteers
- 257 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
- Trial name
- FORTIFI-FLEX (NCT07807163)
- Testing
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
- Where
- 7 sites in United States
- Volunteers
- 160 people
- Sponsor
- Bicara Therapeutics
Melanoma, Non-Small Cell Lung Cancer
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02575404
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Providence Health & Services
High-risk Non-muscle Invasive Bladder Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the…
- Trial name
- NCT03711032
- Testing
- Pembrolizumab, BCG
- Where
- 209 sites in United States, Australia and 28 more
- Volunteers
- 1,397 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
In this study participants with advanced/metastatic adenocarcinoma of the esophagus (EAC), squamous cell carcinoma of the esophagus (ESCC), or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction…
- Trial name
- NCT02559687
- Testing
- pembrolizumab
- Volunteers
- 121 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Ductal Adenocarcinoma
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma…
- Trial name
- NCT05132504
- Testing
- Pembrolizumab, Folfirinox
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine
Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma
Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
This Phase II trial is to see how well single agent chemotherapy and pembrolizumab work elderly patients (≥ 75 years) with advanced non small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, PD-L1 Gene Mutation
- Trial name
- HFHS 21-01 (NCT04754815)
- Testing
- Pembrolizumab, Pemetrexed, Paclitaxel
- Sponsor
- Shirish Gadgeel
High Grade Urothelial Carcinoma, Bladder Cancer
Renal Retention in High Grade Upper Tract Urothelial Cancer
This trial will evaluate the use of combination pembrolizumab and enfortumab vedotin for patients with high grade non-metastatic (cN0/NxMx, no measurable regional lymph nodes, no metastases) upper tract urothelial cancer (UTUC)…
- Conditions
- High Grade Urothelial Carcinoma, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- NCT05656235
- Testing
- Enfortumab vedotin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Melanoma
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.
- Trial name
- NCT03311308
- Testing
- Pembrolizumab Injection [Keytruda], Metformin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yana Najjar
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.